Cargando…
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681930/ https://www.ncbi.nlm.nih.gov/pubmed/36378495 http://dx.doi.org/10.1182/bloodadvances.2022009077 |
| _version_ | 1784834736700522496 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9681930 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96819302022-11-30 Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155. Blood Adv Erratum The American Society of Hematology 2022-11-17 /pmc/articles/PMC9681930/ /pubmed/36378495 http://dx.doi.org/10.1182/bloodadvances.2022009077 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Erratum Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155. |
| title | Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155. |
| title_full | Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155. |
| title_fullStr | Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155. |
| title_full_unstemmed | Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155. |
| title_short | Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155. |
| title_sort | smith cc, levis mj, perl ae, et al. molecular profile of flt3-mutated relapsed/refractory patients with aml in the phase 3 admiral study of gilteritinib. blood adv. 2022;6(7):2144-2155. |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681930/ https://www.ncbi.nlm.nih.gov/pubmed/36378495 http://dx.doi.org/10.1182/bloodadvances.2022009077 |